An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis

• DOI: 10.1007/s11657-012-0070-7
• Publication Date: 2012-03-20T16:49:07Z
• Authors: S. Lekamwasam; J. D. Adachi; D. Agnusdei; J. Bilezikian; S. Boonen; F. Borgström; C. Cooper; A. Diez Perez; R. Eastell; L. C. Hofbauer; J. A. Kanis; B. L. Langdahl; O. Lesnyak; R. Lorenc; E. McCloskey; O. D. Messina; N. Napoli; B. Obermayer-Pietsch; S. H. Ralston; P. N. Sambrook; S. Silverman; M. Sosa; J. Stepan; G. Suppan; D. A. Wahl; J. E. Compston
• Keywords: bone protective therapy; 3. Good health; Bone protective therapy; 03 medical and health sciences; Fracture; 0302 clinical medicine; fracture; 3207 Patología; Antirheumatic Agents; Rheumatic Diseases; 616; 617; Bone mineral density; Humans; Osteoporosis; bone mineral density; 32 Ciencias médicas; Glucocorticoids; FRAX

The use of glucocorticoids in the treatment of medical disorders can lead to rapid bone loss and increased risk of fragility fracture. Updated clinical guidelines are needed that accommodate recent advances in fracture risk assessment and new pharmacological interventions to reduce fracture risk. This document serves as an appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis.